bryostatin 1

a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S*-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-isomer; structure given in first source; activates protein kinase c

Networked: 152 relevant articles (6 outcomes, 39 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Al-Katib, A M: 8 articles (12/2001 - 02/2000)
2.	Mohammad, R M: 8 articles (12/2001 - 02/2000)
3.	Blumberg, Peter M: 6 articles (04/2015 - 07/2006)
4.	Grant, Steven: 6 articles (10/2006 - 05/2002)
5.	Kedei, Noemi: 5 articles (04/2015 - 05/2011)
6.	Wender, Paul A: 5 articles (10/2014 - 11/2002)
7.	Bear, Harry D: 5 articles (11/2013 - 01/2002)
8.	Wall, N R: 5 articles (12/2001 - 02/2000)
9.	Keck, Gary E: 4 articles (04/2015 - 05/2011)
10.	Nakagawa, Yu: 4 articles (10/2014 - 02/2002)

Related Diseases

1.	Neoplasms (Cancer) 04/15/1992 - "Thus, at doses used to treat murine tumors, bryostatin 1 treatment does not affect the clearance of S. " 04/24/2015 - "Bryostatin 1, a complex macrocyclic lactone isolated from Bugula neritina, has been the subject of multiple clinical trials for cancer. " 07/15/2006 - "Bryostatin 1 is currently in clinical trials as a cancer chemotherapeutic agent. " 09/01/1998 - "The development of the NCI human cancer cell line screen, and its application to mechanistic studies through use of COMPARE analyses, are discussed, as is the production of the marine-derived anticancer agent, bryostatin 1, which provides another illustration of a successful approach to solving a supply issue. " 05/01/1996 - "Despite extensive examination of its activities in vitro and anti-tumor effects in vivo, previous studies have failed to document that bryostatin 1 modulates total cellular PKC activity in tumor or normal tissues when administered in vivo. "
2.	Leukemia 07/01/2002 - "Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia." 05/16/2011 - "In U937 human leukemia cells, a second system in which PMA and bryostatin 1 have divergent effects, viz. " 07/01/2002 - "Together, these findings demonstrate that bryostatin 1 can be safely administered as a continuous infusion before and after a split course of HiDAC in patients with refractory leukemia, and identify the bryostatin 1 MTD as 50 microg/m(2) when given by this schedule. " 05/01/1996 - "A similar pattern was observed when bryostatin 1 was incubated with leukemia cells in vitro, raising the possibility that the rapid fall in plasma levels results from intracellular uptake and binding. " 07/25/1991 - "In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells."
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/01/1998 - "Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies." 10/15/2003 - "Bryostatin 1 is known to exhibit in vitro and in vivo activity against chronic lymphocytic leukemia (CLL) cells by inducing their further maturation into plasma-like cells. " 10/15/2003 - "STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1." 04/01/2000 - "Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report." 10/01/1989 - "Peripheral blood cells from nine patients with B-chronic lymphocytic leukemia (B-CLL) were treated in vitro with bryostatin 1 (a macrocyclic lactone derived from a marine invertebrate). "
4.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell) 05/01/1998 - "The down-regulation of multidrug resistance (mdr1) gene expression as detected by competitive reverse transcription-PCR and the antitumor activity of bryostatin 1 (Bryo1) are investigated in a newly established cell line from a patient with relapsed diffuse large cell lymphoma (DLCL). " 09/01/1995 - "Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma." 06/01/1995 - "The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma." 05/01/2012 - "In addition to primary chronic lymphocytic leukemia cells, bryostatin 1 also sensitizes diffuse large B-cell lymphoma and mantle cell lymphoma cells to BL22 induced apoptosis. " 05/01/1998 - "Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts."
5.	Salmonella Infections (Salmonellosis) 04/15/1992 - "Analysis of the first 4 h of Salmonella infection demonstrates that bryostatin 1 does not affect the blood clearance of the bacterium. " 04/15/1992 - "The weight loss is exacerbated by Salmonella infection with mice receiving bryostatin 1 and S. "

Related Drugs and Biologics

1.	Protein Kinase C
2.	Vincristine (Oncovin)
3.	Phosphotransferases (Kinase)
4.	soblidotin (TZT 1027)
5.	Paclitaxel (Taxol)
6.	Cytotoxins
7.	2-chloro-3'-deoxyadenosine
8.	5'-Nucleotidase (5' Nucleotidase)
9.	Deoxycytidine Kinase
10.	Calcium

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intravenous Infusions
3.	Transplants (Transplant)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Combination Drug Therapy (Combination Chemotherapy)